Matching articles for "Pemazyre"

In Brief: A New Indication for Pemigatinib (Pemazyre) (online only)

   
The Medical Letter on Drugs and Therapeutics • April 17, 2023;  (Issue 1674)
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has been approved by the FDA for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor...
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has been approved by the FDA for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. It is the first targeted therapy to be approved in the US for this indication. The drug received accelerated approval from the FDA in 2020 for treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e71-2 | Show Full IntroductionHide Full Introduction

Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • December 28, 2020;  (Issue 1614)
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or...
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. Pemigatinib is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):e208-9 | Show Full IntroductionHide Full Introduction